团队人员

1.  研究组长：陈江帆教授，美国波士顿大学医学院教授，研究生导师。1987至1992年在第三军医大学获创伤外科学博士学位；1987至1993年在宾夕法尼亚医学院获药理学博士学位；1993至1995年在纽约大学石溪分校获药理系博士后；1995至1997年在哈佛大学医学院（麻省总医院神经科），博士后；1997至2000年获美国哈佛大学医学院，麻省总医院神经系，讲师；2000至2001年获美国哈佛大学医学院，麻省总医院神经系，助理教授；2001至2002年获美国波士顿大学，医学院神经系，助理教授；2003至2010年获波士顿大学医学院神经系，副教授 ；2010至2015获波士顿大学医学院神经系，教授；2012至2015在温州医科大学附属眼视光医院担任教授（兼职）；2016至今在温州医科大学附属眼视光学院担任教授（全职）。独立承担研究大脑中化学物质多巴胺和腺苷在帕金森氏症发病机制药理治疗研究超过15年。在腺苷领域已发表超过150篇文章，近五年也发表过50余篇文章。他还被邀担任美国健康研究员基金评委，奥地利科研基金评委，并先后二次在国际学术会议上担任分会主席。

实验室目前拥有国家自然科学基金重点项目1项，国家重点研发计划“重大慢性非传染性疾病防控研究”重点专项“帕金森病早期诊断生物标记及综合诊断指标体系研发”项目（参加）；国家自然科学基金青年项目4项；浙江省自然科学基金一般项目1项；浙江省自然科学基金青年基金项目3项；温州市科学技术局公益性科技计划项目4项

2.  工作人员：李智慧、任湘鹏、高英、周建宏、张莉平、郑武、郭卫、王琴、Sergii Vakal、张书雅、何艳、陈行军、叶芬芬

研究方向

  1. 腺苷A2A受体控制认知：工作记忆

  2. 腺苷A2A受体和帕金森病

  3. 腺苷A2A受体控制小胶质细胞/突触修剪

  4. 腺苷A2A受体控制认知：认知可塑性

  5. 腺苷A2A受体对脑机接口控制

  6. 腺苷A2A受体和神经胶质瘤治疗

  7. 腺苷A2A受体对脑机接口控制

  8. 腺苷A2A受体对视网膜血管化调控

  9. 腺苷A2A受体控制认知：操作性行为

Laboratory of Molecular Neuroscience

Team members

1.  Principle Investigator: Jiang-Fan Chen, MD, PhD

Jiang-Fan Chen was awarded as National "Thousands of People Plan" innovative talents. He obtained his Ph.D. degree in Traumatized Science from Third Military Medical University in 1992. He obtained his Ph.D. degree in Pharmacology from Pennsylvania medical school in 1993.From 1993-1995, he got training as a postdoctoral follow in Dept. Pharmacology, SUNY at Stony Brook (with C. M. Malbon),then from 1995-1997 he got training as a postdoctoral fellow in Dept. Neurology, Mass. Gen. Hospital/Harvard Med. Sch. (with JS. Fink).During 1997-2000, he was the instructor of Neurology in Harvard Medical School and in 2001 he became an assistant professor in Department of Neurology in Harvard Medical School, USA. From 2001 to 2002, he worked as an assistant professor in Department of Neurology, Boston University School of Medicine, then from 2003-2009 he worked as an associate professor in Department of Neurology, Boston University School of Medicine, USA. From 2010, he worked as a Professor in Department of Neurology, Boston University School of Medicine, USA. He joined the Eye Hospital, Wenzhou Medical University in 2011 as a Principal Investigator. He independently undertook to study the pharmacological treatment of dopamine and adenosine in the brain for more than 15 years in the pathogenesis of Parkinson's disease. More than 150 articles have been published in the field of adenosine, and more than 50 articles have been published in the last five years. He was also invited to serve as the judge of the health research fund of the United States, the Austria scientific research fund, and as the chairman of the international academic conference two times.

2.  Team Staff: Zhihui Li, Xiangpeng Ren, Ying Gao, Jianghong Zhou, Liping Zhang, Wu Zheng, Wei Guo, Qin Wang,  Sergii Vakal, Shuya Zhang, Yan He, Xingjun Chen, Fenfen Ye

Scope of Research Proposal

1. Adenosine A2A Receptor control cognition: working memory

2. Adenosine A2A receptor and Parkinson's disease

3. Adenosine A2A receptor controls microglia / synaptic pruning

4. Adenosine A2A receptor control cognition: cognitive plasticity

5. Adenosine A2A receptor is controlled by the brain machine interface

6. Adenosine A2A receptor and glioma treatment

7. Adenosine A2A receptor is controlled by the brain machine interface

8. Adenosine A2A receptor regulates the vascularization of the retina

9. Adenosine A2A receptor controls cognition: operational behavior